Visualization of transcoronary ablation of septal hypertrophy in patients with hypertrophic obstructive cardiomyopathy: a comparison between cardiac MRI, invasive measurements and echocardiography

[1]  M. Desai,et al.  Management of hypertrophic cardiomyopathy. , 1993, Heart disease and stroke : a journal for primary care physicians.

[2]  Dieter Horstkotte,et al.  Cardiac volumetry in patients with heart failure and reduced ejection fraction: a comparative study correlating multi-slice computed tomography and magnetic resonance tomography. Reasons for intermodal disagreement , 2009, Clinical Research in Cardiology.

[3]  T. Schlosser,et al.  A simple MR algorithm for estimation of myocardial salvage following acute ST segment elevation myocardial infarction , 2009, Clinical Research in Cardiology.

[4]  Achim Seeger,et al.  Adenosine stress cardiac magnetic resonance imaging for the assessment of ischemic heart disease , 2008, Clinical Research in Cardiology.

[5]  P. Boesiger,et al.  High spatial resolution myocardial perfusion cardiac magnetic resonance for the detection of coronary artery disease , 2008, European heart journal.

[6]  C. Stellbrink,et al.  Survival after transcoronary ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy (TASH): a 10 year experience , 2008, Clinical Research in Cardiology.

[7]  G. Pilz,et al.  Cardiac magnetic resonance imaging: an essential diagnostic aid in suspected myocardial re-infarction in a 40 year old woman , 2008, Clinical Research in Cardiology.

[8]  R. Carlos,et al.  Diagnostic performance of stress cardiac magnetic resonance imaging in the detection of coronary artery disease: a meta-analysis. , 2007, Journal of the American College of Cardiology.

[9]  D. Fassbender,et al.  One-year follow-up of percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy in 312 patients: predictors of hemodynamic and clinical response , 2007, Clinical Research in Cardiology.

[10]  Maria I Altbach,et al.  Cardiac MRI is Complementary to Echocardiography in the Assessment of Cardiac Masses , 2007, Echocardiography.

[11]  R. Zahn,et al.  Diagnosis of left ventricular myxoma with cardiac magnetic resonance imaging , 2007, Clinical Research in Cardiology.

[12]  N. Lakkis,et al.  Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a systematic review of published studies. , 2006, Journal of interventional cardiology.

[13]  O. Strohm,et al.  Cardiac magnetic resonance in outpatients in Germany--indications, complications and protocol suggestions from a high-volume center. , 2006, International journal of cardiology.

[14]  I. Sathyamurthy.  Transcoronary ablation of septal hypertrophy (Tash). , 2006, Indian heart journal.

[15]  J. Veselka,et al.  Effects of varying ethanol dosing in percutaneous septal ablation for obstructive hypertrophic cardiomyopathy on early hemodynamic changes. , 2005, The American journal of cardiology.

[16]  Werner Klein,et al.  Clinical applications of cardiovascular magnetic resonance. , 2005, Current pharmaceutical design.

[17]  Eckart Fleck,et al.  Magnetic Resonance Low-Dose Dobutamine Test Is Superior to Scar Quantification for the Prediction of Functional Recovery , 2004, Circulation.

[18]  Barry J Maron,et al.  American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice G , 2003, Journal of the American College of Cardiology.

[19]  T. Lawrenz.  754 What is the correct amount of ethanol in the catheter based treatment for hypertrophic obstructive cardiomyopathy , 2003 .

[20]  E. Braunwald.  Hypertrophic cardiomyopathy--the benefits of a multidisciplinary approach. , 2002, The New England journal of medicine.

[21]  S. Ommen,et al.  Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. , 2001, Journal of the American College of Cardiology.

[22]  H. Rakowski,et al.  To ablate or operate? that is the question! , 2001, Journal of the American College of Cardiology.

[23]  A. Knez,et al.  Pressure-guided nonsurgical myocardial reduction induced by small septal infarctions in hypertrophic obstructive cardiomyopathy. , 2001, Journal of the American College of Cardiology.

[24]  S. Nagueh,et al.  Regression of Left Ventricular Hypertrophy After Nonsurgical Septal Reduction Therapy for Hypertrophic Obstructive Cardiomyopathy , 2001, Circulation.

[25]  J. Kuijer,et al.  Quantification of regional contractile function after infarction: strain analysis superior to wall thickening analysis in discriminating infarct from remote myocardium. , 2001, Journal of the American College of Cardiology.

[26]  O. Simonetti,et al.  The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. , 2000, The New England journal of medicine.

[27]  O. Schober,et al.  Changes in the left ventricular outflow tract after transcoronary ablation of septal hypertrophy (TASH) for hypertrophic obstructive cardiomyopathy as assessed by transoesophageal echocardiography and by measuring myocardial glucose utilization and perfusion. , 1999, European heart journal.

[28]  H. Kuhn,et al.  Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH). Catheter interventional treatment for hypertrophic obstructive cardiomyopathy. , 1999, European heart journal.

[29]  B. Maron.  New interventions for obstructive hypertrophic cardiomyopathy: promise and prudence. , 1999, European heart journal.

[30]  K. Borisov,et al.  Management of Symptomatic Hypertrophic Obstructive Cardiomyopathy - Long-Term Results after Surgical Therapy , 1999, The Thoracic and cardiovascular surgeon.

[31]  U. Gleichmann,et al.  Percutaneous transluminal septal ablation in hypertrophic obstructive cardiomyopathy. , 1999, The Thoracic and cardiovascular surgeon.

[32]  B. Maron,et al.  Perspectives on the role of new treatment strategies in hypertrophic obstructive cardiomyopathy. , 1999, Journal of the American College of Cardiology.

[33]  U. Gleichmann,et al.  Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respect to intraprocedural myocardial contrast echocardiography. , 1998, Circulation.

[34]  M. Verani,et al.  Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. , 1998, Circulation.

[35]  E. Erdmann,et al.  Dobutamine magnetic resonance imaging predicts contractile recovery of chronically dysfunctional myocardium after successful revascularization. , 1998, Journal of the American College of Cardiology.

[36]  L. Fananapazir,et al.  Therapeutic options in patients with obstructive hypertrophic cardiomyopathy and severe drug-refractory symptoms. , 1998, Journal of the American College of Cardiology.

[37]  R. Kerber,et al.  Measurement of left ventricular volume using a right ventricular intracardiac ultrasound transducer: experimental validation , 1998 .

[38]  H. Kuhn,et al.  Induction of subaortic septal ischaemia to reduce obstruction in hypertrophic obstructive cardiomyopathy. Studies to develop a new catheter-based concept of treatment. , 1997, European heart journal.

[39]  D. Harrington,et al.  Nonsurgical septal reduction for hypertrophic obstructive cardiomyopathy: outcome in the first series of patients. , 1997, Circulation.

[40]  R. Robbins,et al.  Long-term results of left ventricular myotomy and myectomy for obstructive hypertrophic cardiomyopathy. , 1996, The Journal of thoracic and cardiovascular surgery.

[41]  W. Williams,et al.  Hypertrophic cardiomyopathy. Clinical spectrum and treatment. , 1995, Circulation.

[42]  U. Sigwart.  Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy , 1995, The Lancet.

[43]  H. Klues,et al.  Left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy: increase in gradient after exercise. , 1992, Journal of the American College of Cardiology.

[44]  R. Bonow,et al.  Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (1). , 1987, The New England journal of medicine.

[45]  B. Maron,et al.  Symptomatic status and prognosis of patients after operation for hypertrophic obstructive cardiomyopathy: efficacy of ventricular septal myotomy and myectomy. , 1983, European heart journal.

[46]  H. Kuhn,et al.  Clinical course and prognosis of patients with typical and atypical hypertrophic obstructive and with hypertrophic non-obstructive cardiomyopathy. , 1983, European heart journal.

[47]  B. Gilbert,et al.  Hypertrophic cardiomyopathy: subclassification by m mode echocardiography. , 1980, The American journal of cardiology.

[48]  A. DeMaria,et al.  Recommendations Regarding Quantitation in M-Mode Echocardiography: Results of a Survey of Echocardiographic Measurements , 1978, Circulation.

[49]  W. Henry,et al.  Operative Treatment in Hypertrophic Subaortic Stenosis: Techniques, and the Results of Pre and Postoperative Assessments in 83 Patients , 1975, Circulation.

[50]  V. Hombach,et al.  Diagnostic performance of magnetic resonance first pass perfusion imaging is equally potent in female compared to male patients with coronary artery disease , 2009, Clinical Research in Cardiology.

[51]  O. Schober,et al.  Transcoronary ablation of septal hypertrophy (TASH): a new treatment option for hypertrophic obstructive cardiomyopathy , 2000, Zeitschrift für Kardiologie.

[52]  R. Bonow,et al.  Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (2). , 1987, The New England journal of medicine.